IYH iShares U.S. Healthcare ETF
Company Analysis
Latest News
Novo Nordisk tests semaglutide implant, countering Eli Lilly in obesity market
Novo Nordisk partnered with Vivani Medical to evaluate NPM-139, a miniature subdermal implant for semaglutide. This active ingredient currently powers the...
Novartis to acquire Myricx Bio for $1.5B, strengthening cancer therapy pipeline
Novartis signed a definitive agreement to acquire Myricx Bio for up to $1.5 billion. The UK-based preclinical oncology company will receive an upfront cash...
Novartis to Acquire Myricx Bio for $1.5B, Strengthening Cancer Drug Pipeline
Novartis entered an agreement to acquire UK-based biotechnology company Myricx Bio for up to $1.5 billion. The deal includes an initial $1.1 billion upfront...
Amgen Tavneos Data Retracted From NEJM, Citing FDA Integrity Probe
The New England Journal of Medicine retracted pivotal data for Amgen’s autoimmune drug, Tavneos. Two academic authors requested the retraction following an...
Moderna Surges 10% as FDA Panel Unanimously Backs mRNA Flu Vaccine
An FDA advisory committee voted 16-0 to recommend Moderna's mRNA-based influenza vaccine. This unanimous endorsement signals a high likelihood of full FDA...
CMS launches Medicare GLP-1 Bridge, capping Wegovy and Zepbound at $50
CMS officially launched the Medicare GLP-1 Bridge program on July 1, 2026. Eligible Medicare Part D beneficiaries can now access Wegovy and Zepbound for a...
AbbVie Wins FDA Approval for Pediatric Skyrizi, First IL-23 for Kids
The U.S. Food and Drug Administration (FDA) approved AbbVie's Skyrizi (risankizumab-rzaa) for children aged 6 and older. This approval covers pediatric...
Sandoz Challenges Eli Lilly With Generic Mounjaro and Zepbound Filings
The FDA accepted two applications from Swiss drugmaker Sandoz for generic versions of Eli Lilly’s tirzepatide medications, Mounjaro and Zepbound. These...
Merck KGaA Buys Bio-Techne for $11.3 Billion, Expanding Research Tools
Merck KGaA will acquire U.S. biotech firm Bio-Techne for $11.3 billion. The all-cash offer provides $73 per share to Bio-Techne investors. This price...
🟢 IYH is trading 3% up today on defensive rotation and healthcare M&A activity
IYH is trading 3% up today as investors rotate toward defensive, non-tech sectors following recent pressure in technology and AI-related names. • A volatile...
Merck KGaA Buys Bio-Techne for $11.3 Billion, Expanding High-Growth Life Sciences
Merck KGaA entered a definitive agreement to acquire Bio-Techne Corp. for $73 per share in cash. The transaction represents a total enterprise value of...
Merck Gains EU Approval for Keytruda-Padcev, Cutting Bladder Cancer Death Risk 50%
Merck received European Commission approval for KEYTRUDA in combination with the antibody-drug conjugate Padcev. The regimen treats adult patients with...
REGENXBIO Clears FDA Hurdle for NAVSUNLI™, No New Trials Needed
REGENXBIO reached an agreement with the FDA on a path to resubmit its Biologics License Application (BLA) for NAVSUNLI™. This one-time gene therapy targets...
U.S. Probes German Drug Pricing, Threatening Tariffs Following Eli Lilly Investment Cuts
The U.S. government initiated a formal trade investigation into Germany’s proposed drug-pricing reforms under Section 301 of the Trade Act of 1974. This probe...
FDA Issues High-Risk Alert for Johnson & Johnson's Abiomed Heart Pump
The U.S. Food and Drug Administration (FDA) has issued an alert for a 'potentially high-risk' leakage issue with Abiomed's Impella heart pump introducer kits....
Merck Wins FDA Approval for CAPVAXIVE in At-Risk Children
Merck received FDA approval for an expanded indication of its CAPVAXIVE vaccine. The approval covers children and adolescents aged 2 through 17 with underlying...
uniQure Surges as FDA Eases Path for Huntington’s Gene Therapy
The FDA reversed its stance to allow uniQure to file for accelerated approval of AMT-130, a Huntington's disease gene therapy. The agency will accept...
Pfizer settles 5,000 lawsuits, resolving Depo-Provera brain tumor claims
Pfizer reached a settlement in principle to resolve more than 5,000 lawsuits involving its Depo-Provera birth control shot. A Monday court filing confirmed the...
Johnson & Johnson invests $1B in ACUVUE, strengthening domestic supply chains
Johnson & Johnson will invest over $1 billion to expand its Vision operations in Jacksonville, Florida. The capital will scale domestic manufacturing,...
Legend Biotech Reports 100% Response Rate for In Vivo CAR-T Therapy
Legend Biotech (NASDAQ: LEGN) released clinical proof-of-concept data for LB2501, an investigational in vivo CAR-T cell therapy. The company presented the...